Publications

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.

Scotland G. et al, (2025), Diabet Med, 42

Experience of linking to the NHS diabetic eye screening programme records in the ASCEND-eye randomized trial and recommendations for improvement.

Sammons E. et al, (2025), Contemp Clin Trials Commun, 45

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Judge PK. et al, (2025), Nephrol Dial Transplant, 40, 1175 - 1186

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730

Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes.

Sammons E. et al, (2025), BMJ Open, 15

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial.

Sammons EL. et al, (2024), BMC Ophthalmol, 24

LDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL

Judge P. et al, (2024), Nephrology Dialysis Transplantation

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group ., (2024), Diabet Med, 41

Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM Evid, 3

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129

ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 771 - 779

Effects of Aspirin and Omega-3 Fatty Acids on Composite and Subdomain Scores from the NEI-VFQ-25 Questionnaire: The ASCEND-Eye Randomized Controlled Trial

Sammons EL. et al, (2024)

ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 526 - 533

Search results (36)